搜索结果41-50 的 26072 / Adenocarcinoma

  1. 泌尿科- 临床试验- 妙佑医疗国际

    DNA Methylation in Adenocarcinoma of the Prostate: Tissue Validation of Biomarkers and Pilot Testing in Blood. Rochester, Minn. The study will be performed ...

  2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma ...

  3. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

    The primary purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with ...

  4. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  5. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  6. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

    The primary purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with ...

  7. 胸腔外科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, and EGFR mutations and effectively evaluate these patients with respect to key outcomes of interest including overall survival, time to ...

  8. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    DISEASE STATE - Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed. - ...

  10. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...